David Marek

Dave Marek


Mr. Marek is a veteran biopharmaceutical executive with over 30 years’ successful industry experience.  Mr. Marek previously served as chief executive officer and as a board director of Myovant Sciences, Inc., where he led the evolution from clinical-stage to commercial-stage with launches of three therapeutics focused on hormone-sensitive oncology and women’s health prior to the company’s sale to Sumitovant Biopharma Ltd.  Before Myovant, Mr. Marek served as chief commercial officer of Axsome Therapeutics, Inc., where he led the buildout of commercial capabilities in preparation for anticipated product launches.  Prior to joining Axsome, Mr. Marek held the position of General Manager of the Neuroscience business unit at Amgen, Inc. (Amgen), where he led the U.S. commercialization strategy and launch of Aimovig® for migraine prevention. Before Amgen, Mr. Marek served in a number of leadership roles including Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD Health Corp. Mr. Marek began his career at Eli Lilly and Company, followed by AstraZeneca, where he served in a variety of marketing and sales roles of increasing responsibility. He earned his Bachelor of Arts degree in Business Administration from Washington State University.

Back to Team